Into 2019: Risk, Uncertainty and a Return to Product Focus

Posted by Brian Chapman on January 23, 2019

Looking ahead to what the medtech industry can expect in 2019, I see a continuation of some of the greatest accomplishments of 2018, such as ongoing collaboration with regulatory bodies and real-world evidence driving more reimbursement discussions, as well as the brave new world of digital health continuing to buoy how our industry can help patients.


>
Read More

Ushering in 2019: Medtech’s Year to Come

Posted by Tobi Laczkowski on January 17, 2019

A new year has come, so it’s time to take a step back and make some observations about the industry’s 2018 evolution and provide some thoughts on how 2019 is shaping up.


>
Read More

How the FDA's New 510(k) Guidelines Could Help or Hurt Medtech

Posted by Sundeep Karnik on January 14, 2019

Matt Singer co-wrote this blog post with Sundeep Karnik.

Recently, the FDA announced new steps to modernize its 510(k) regulatory clearance pathway. This is the first major overhaul of a process that has been in place since 1976. The FDA intends to implement three major changes:


>
Read More

A ZS Expert Weighs in on the Data-Driven Transformation of Life Sciences

Posted by ZS Editors on December 14, 2018

Digital health is well-positioned to help pharmaceutical and medtech companies create more value for patients. However, the success of digital health solutions is reliant on innovative commercial models—models with a strong focus on data and analytics, and outcomes. 


>
Read More

Vital Signs: How Medtech Companies Can Heal the Aches and Pains of Modern Healthcare Systems

Posted by Will Randall on November 15, 2018

Hospital spending has grown 15% and patient admissions are up 20% since 2009. Despite some efficiency gains, the provider financial deficit is large and growing, and patients are waiting longer than ever before for treatment in a system stretched to capacity. Sound familiar?


>
Read More